By Brad Sorensen, CFA
NASDAQ:TELO
READ THE FULL TELO RESEARCH REPORT
Telomir Pharmaceuticals (NASDAQ:TELO) is a preclinical stage biopharmaceutical company developing a product designed to reverse biological aging and degenerative diseases. Previously reported preclinical tests have shown evidence that Telomir-1, the company’s primary therapy, can lengthen telomeres, and initial animal testing illustrates the potential impact. In fact, the company recently released results from one of those tests, which, according to CEO Erez Aminov, “confirms Telomir-1 can reverse biologic aging, extending life while preserving health.”
Preclinical test results recently released further confirm the CEO’s statement and our belief in TELO. The company announced that a preclinical study showed that Telomir-1 can reset abnormal DNA methylation patterns, which reverses the cancer-induced gene silencing in tumor suppressors. That’s the scientific way of saying that there are indications that Telomir-1 has the potential to have the ability to fight multiple aggressive cancers—adding to the conditions Telomir-1 has shown indications of being able to treat.
Getting into the scientific detail—Telomir-1, according to the company, reverses DNA methylation of CDKN2A, a master tumor suppressor gene silenced in many aggressive cancers. CDKN2A is one of the body's natural defenses against cancer. Also referred to as the "cell cycle brake," this gene tells cells when to stop dividing and helps damaged cells self-destruct. In many cancers, CDKN2A is switched off by abnormal DNA methylation, leaving tumors free to grow unchecked. By resetting this methylation, Telomir-1 appears to turn the brake back on - restoring a critical safeguard that cancer cells had disabled.
These results continue the mounting evidence that Telomir-1 has the potential to have a major impact on the worst parts of the aging process, which would have an almost unlimited market potential. We continue to recommend investors take a look at TELO ahead of the human trials that are planned for early next year.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCH to receive our articles and reports emailed directly to you each morning. Please visit our website for additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks SCR provides and Zacks SCR receives payments totaling a maximum fee of up to $50,000 annually for these services provided to or regarding the issuer. Full Disclaimer HERE.